Alfred Mann, a medical device entrepreneur who helped develop several groundbreaking technologies, died yesterday at age 90, shortly after stepping down from a pair of companies he founded. Mann founded 17 companies over his 70-year career, in industries ranging from aerospace to medtech, according to the L.A. Times. After Johns Hopkins University researchers in 1969 […]
Update: Added comments from Penumbra CEO Adam Elsesser Penumbra (NYSE:PEN) yesterday launched its POD packing coil in the U.S., designed as a complimentary addition to the company’s Ruby and POD embolization devices. The focus on peripheral vascular products has been significant for the Alameda, Calif.-based company, despite only entering the field a little over a year […]
Penumbra (NYSE:PEN) yesterday said the net proceeds from its just-closed initial public offering were roughly $124.5 million, including an underwriters over-allotment worth $18 million. Alameda, Calif.-based Penumbra floated 4.6 million shares at $30 apiece, for gross proceeds of $138 million. PEN shares opened at $40 each Sept. 18, peaking at $42 in their 1st day of […]
Penumbra priced its initial public offering today, saying it plans to raise $120 million by floating 4 million shares at $30 apiece. The company is also offering a 30-day underwriters option for an additional 600,000 shares. Penumbra shares are slated to trade on the New York Stock Exchange today under the “PEN” symbol. When Alameda, Calif.-based Penumbra registered the IPO last […]
Penumbra today set the range for its pending initial public offering, saying it plans to float 3.8 million shares at $25 to $28 apiece. That works out to a range of $95 million to $106.4 million, $100.7 million at the midpoint. When Alameda, Calif.-based Penumbra registered the IPO last month it estimated the offering could fetch as […]
Penumbra, fresh off its latest entry into the peripheral vascular market, last week registered for an initial public offering worth $115 million. Alameda, Calif.-based Penumbra also makes devices for treating neurovascular conditions including hemorrhagic and ischemic stroke. The company reported sales of $125.5 million last year, up 41.3% over 2013. Founded in 2004, Penumbra said it employs […]
Penumbra said last week that a study of its Ace64 thrombectomy system shows the device to be effective in patients with acute ischemic stroke. The data from the study was presented at the Society of NeuroInterventional Surgery’s annual meeting in San Francisco. The 117-patient, 6-country study reported a 96% revascularization rate in acute ischemic stroke […]
Penumbra said today that it has received 510(k) clearance from the FDA for its Ace64 aspiration thrombectomy device, based on data from the Mr. Clean trial and additional randomized controlled stroke trials.